Brokerages Expect Sarepta Therapeutics Inc (SRPT) Will Announce Earnings of -$0.67 Per Share

Equities research analysts expect Sarepta Therapeutics Inc (NASDAQ:SRPT) to announce ($0.67) earnings per share for the current quarter, Zacks Investment Research reports. Nine analysts have made estimates for Sarepta Therapeutics’ earnings, with estimates ranging from ($1.03) to ($0.32). Sarepta Therapeutics reported earnings of ($0.37) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 81.1%. The firm is scheduled to issue its next quarterly earnings report on Thursday, March 7th.

According to Zacks, analysts expect that Sarepta Therapeutics will report full-year earnings of ($1.94) per share for the current fiscal year, with EPS estimates ranging from ($2.30) to ($1.61). For the next financial year, analysts anticipate that the business will report earnings of ($1.89) per share, with EPS estimates ranging from ($2.96) to ($0.45). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Sarepta Therapeutics.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, October 24th. The biotechnology company reported ($1.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.86) by ($0.29). Sarepta Therapeutics had a negative net margin of 89.46% and a negative return on equity of 23.67%. The business had revenue of $78.49 million during the quarter, compared to analyst estimates of $78.84 million.

Several equities analysts have recently commented on the company. BidaskClub lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, August 16th. Credit Suisse Group assumed coverage on Sarepta Therapeutics in a research note on Thursday, September 6th. They issued an “outperform” rating and a $178.00 price target on the stock. Citigroup upped their price target on Sarepta Therapeutics from $174.00 to $188.00 and gave the company a “buy” rating in a research note on Tuesday, November 6th. HC Wainwright set a $267.00 price target on Sarepta Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 9th. Finally, Sanford C. Bernstein assumed coverage on Sarepta Therapeutics in a research note on Friday, October 12th. They issued an “outperform” rating and a $170.00 price target on the stock. Three analysts have rated the stock with a hold rating, twenty-four have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $169.19.

In other news, CEO Douglas S. Ingram bought 16,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 15th. The shares were purchased at an average price of $125.26 per share, with a total value of $2,004,160.00. Following the purchase, the chief executive officer now owns 399,250 shares in the company, valued at $50,010,055. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the stock in a transaction dated Thursday, November 1st. The stock was sold at an average price of $140.50, for a total value of $936,713.50. Following the transaction, the director now directly owns 126,534 shares in the company, valued at approximately $17,778,027. The disclosure for this sale can be found here. 7.90% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. First Quadrant L P CA purchased a new stake in Sarepta Therapeutics during the 3rd quarter worth about $130,000. Rockefeller Capital Management L.P. purchased a new stake in Sarepta Therapeutics during the 2nd quarter worth about $162,000. Ffcm LLC purchased a new stake in Sarepta Therapeutics during the 3rd quarter worth about $162,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new stake in Sarepta Therapeutics during the 2nd quarter worth about $185,000. Finally, Keybank National Association OH purchased a new stake in Sarepta Therapeutics during the 2nd quarter worth about $206,000. 89.84% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Sarepta Therapeutics stock opened at $125.46 on Friday. Sarepta Therapeutics has a 52 week low of $50.68 and a 52 week high of $176.50. The firm has a market capitalization of $8.89 billion, a PE ratio of -76.50 and a beta of 1.59. The company has a current ratio of 8.85, a quick ratio of 7.84 and a debt-to-equity ratio of 0.65.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

Recommended Story: Calculate Your Return on Investment (ROI)

Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply